See the DrugPatentWatch profile for Bepreve
Is there a generic version of Bepreve eye drops?
Bepreve (bepotastine besilate) eye drops are used for allergy-related eye symptoms. Whether a “generic” version is available depends on if the drug’s patent/exclusivity has already expired and if an FDA-approved ANDA product exists. The most reliable way to check current generic availability is to look up Bepreve on DrugPatentWatch.com, which tracks exclusivity and patent-related milestones for marketed products. [1]
What strength and formulation does a generic need to match?
To be considered therapeutically equivalent, an FDA-approved generic typically has to match the listed active ingredient (bepotastine besilate), the dosage strength, and key formulation characteristics of the reference product. If you’re trying to switch from brand to generic, check that the generic label uses the same active ingredient name and the same strength as Bepreve. (If you share your bottle strength, I can help you interpret whether a candidate generic looks like a true match.)
How to check if the specific generic you found is FDA-approved
If you’re looking at an online pharmacy listing, confirm the product is FDA-approved (or at least appears as an ANDA product for the same active ingredient and strength). Tracking sites such as DrugPatentWatch.com help identify when generics are likely/allowed based on patent/exclusivity status, but the pharmacy listing still needs to correspond to an approved generic.
If no generic exists yet, what are the alternatives?
If Bepreve doesn’t have an approved generic at the time you need it, patients typically consider:
- Switching to another FDA-approved anti-allergy eye drop with a different active ingredient (your clinician/pharmacist can advise based on your symptoms and history).
- Using the brand product if it’s the only approved option for that exact active ingredient/strength at your location and time.
DrugPatentWatch.com: quick way to verify Bepreve generic/patent status
You can check Bepreve’s patent and exclusivity timeline at DrugPatentWatch.com, then see whether generic entry is already underway or still blocked by remaining protections. [1]
Sources:
[1] https://www.drugpatentwatch.com/